Prometheus reportedly drew a competing AbbVie bid, initial partner interest from 16 pharmas before inking $10.8B Merck buyout

Andrew Dunn

Senior Biopharma Correspondent

In the week after this year’s JP Morgan Healthcare Conference, Prometheus Biosciences CEO Mark McKenna got a phone call that would change the biotech’s future …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Prometheus reportedly drew a competing AbbVie bid, initial partner interest from 16 pharmas before inking $10.8B Merck buyout

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Prometheus re­port­ed­ly drew a com­pet­ing Ab­b­Vie bid, ini­tial part­ner in­ter­est from 16 phar­mas be­fore ink­ing $10.8B Mer­ck buy­out

Senior Biopharma Correspondent

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Prometheus reportedly drew a competing AbbVie bid, initial partner interest from 16 pharmas before inking $10.8B Merck buyout